Bromantane is investigated as a tool compound in neuropsychopharmacology, exercise
physiology, and neurotransmitter regulation research. Documented research applications include:

• Tyrosine hydroxylase (TH) transcriptional regulation — mRNA and protein expression studies in dopaminergic neurons
• AADC (DOPA decarboxylase) activity modulation in serotonergic and dopaminergic systems
• Dopamine biosynthesis research — mechanistic comparison with reuptake inhibitor pharmacology
• GABAergic anxiolytic pharmacology — GABA-A receptor modulation without benzodiazepine site classical agonism
• Actoprotector pharmacology — physical performance and fatigue resistance models in rodents
• Hypoxia tolerance research — cardiorespiratory stress model studies
• Adamantane compound structure-activity relationship (SAR) pharmacology
• Monoamine synthesis vs. release/reuptake pharmacology comparative research

Bromantane is not approved for any therapeutic or performance-enhancement indication
and is supplied strictly for laboratory-based scientific investigation.

The mechanistic distinction that makes Bromantane of particular research interest
is its mode of dopaminergic action. Classical psychostimulants (amphetamine, cocaine)
primarily increase synaptic dopamine by stimulating vesicular release or inhibiting
the dopamine transporter (DAT), producing rapid increases in synaptic dopamine that
lead to post-dose neurochemical depletion and, with repeated use, receptor
downregulation and tolerance. Conventional antidepressants (SSRIs, SNRIs) target
monoamine reuptake transporters at the synapse. Bromantane instead acts upstream at
the level of dopamine biosynthesis, upregulating tyrosine hydroxylase gene expression
— the rate-limiting enzymatic step — and AADC activity. This results in increased
neuronal dopamine production rather than forced synaptic efflux, a mechanism proposed
to explain the absence of classical stimulant tolerance and withdrawal in rodent
exposure models. For researchers studying the neurobiology of dopamine regulation,
Bromantane represents a pharmacological tool with a unique biosynthetic action point.

Bromantane’s poor aqueous solubility (estimated <0.1 mg/mL in water or PBS) is a
direct consequence of its structural components: the adamantane cage is a rigid
hydrocarbon structure with no hydrogen-bond donor or acceptor capacity, and the
para-bromophenyl ring adds significant lipophilicity. Combined, these structural features
produce a logP of approximately 4.8, placing Bromantane in the highly lipophilic range
that requires organic co-solvent vehicle systems. Standard research practice is to prepare
a concentrated master stock in DMSO (10–50 mg/mL) and dilute into aqueous media immediately
before use, maintaining final DMSO concentration at ≤0.1% to avoid vehicle cytotoxicity
in cell culture systems. For in vivo rodent studies, hydroxypropyl-β-cyclodextrin (HPβCD)
complexation provides an aqueous-compatible vehicle that significantly improves apparent
solubility. Baltic Peptides’ prepared solution format uses an appropriate organic vehicle
pre-formulated for research applications, eliminating the need for in-laboratory stock
preparation from powder. Regardless of vehicle, always include matched vehicle-alone
controls in all Bromantane biological experiments.

A purity specification of ≥99% indicates that at least 99% of the total material,
by mass, is confirmed to be intact Bromantane (MW 336.25 g/mol), with the remaining
fraction comprising quantified impurities at or below 1% total — determined by
reverse-phase HPLC with UV detection at the aromatic absorption maximum. For Bromantane,
the most analytically important impurity to exclude is the debrominated parent compound
(adamantyl-aniline, MW 257 g/mol), which would lack the bromine pharmacophore and
exhibit a different biological activity profile. Mass spectrometry provides definitive
identity confirmation through the characteristic ⁷⁹Br/⁸¹Br isotope doublet at nominal
masses 335/337 Da (approximately 1:1 intensity ratio) — a pattern unique to
monobrominated compounds that cannot be mimicked by any structurally analogous
impurity. This isotope verification is incorporated into Baltic Peptides’ standard
release protocol for Bromantane.

Yes. Baltic Peptides issues a batch-specific Certificate of Analysis for every
production batch of Bromantane research compound. Each COA documents HPLC purity
data including quantified impurity profiling, mass spectrometry identity confirmation
with bromine isotope pattern data, lot number, manufacturing and testing dates, and
the analytical method parameters applied by the independent testing laboratory.
Researchers may request the current batch COA via the Baltic Peptides support portal
prior to or following purchase. Historical lot documentation is archived and available
upon inquiry.

Baltic Peptides supplies Bromantane in two research-grade formats:

• Crystalline powder: The highest-purity format, providing maximum flexibility for
  researchers who require custom concentration preparation, specific vehicle selection,
  or gravimetric dosing accuracy. Requires in-laboratory dissolution in DMSO or other
  appropriate organic solvent before use. Preferred for researchers with established
  stock solution preparation workflows and access to analytical balance and appropriate
  solvents.
• Prepared solution: A pre-formulated research solution at a defined concentration
  in an appropriate organic vehicle, ready for direct dilution into experimental media.
  Eliminates powder handling, reduces dissolution variability, and is preferred for
  researchers who require immediate availability, consistent vehicle composition, or
  who are conducting higher-volume experimental workflows. The formulation vehicle
  is documented on the COA and product label.

Both formats are analytically equivalent in terms of compound purity and are covered
by the same third-party COA documentation. Format selection should be based on
the specific experimental design and laboratory capabilities of the research group.

Bromantane powder is dispatched in sealed, dry, light-protected containers — typically
amber glass or opaque packaging appropriate for a stable crystalline research compound.
Prepared solution format is dispatched refrigerated in sealed amber vials with
appropriate light-protective outer packaging. Baltic Peptides dispatches from within
the EU, providing shorter transit times for European research institutions and
reducing customs exposure. Cold-chain packaging is standard for solution format orders;
powder orders are dispatched at ambient temperature given the compound’s thermal
stability in its crystalline form. Each shipment includes product labelling stating
lot number, compound identity, concentration (for solution), storage conditions,
and research-use-only classification. Expedited shipping is available for
time-sensitive research requirements on request.